by Biocross | Oct 29, 2016 | Press release
Biocross S.L., a biotechnology company focused on the development of innovative technologies for the diagnosis of Alzheimer’s disease and the identification of at-risk individuals, today announced that their Chief Executive Officer Matt Mittino will present the...
by Biocross | Sep 29, 2016 | Press release
Biocross to participate in the 8th International Meeting on Biotechnology, Biospain 2016, which takes place in Bilbao (Vizcaya), September 28–30, 2016. Biospain has become the main scientific, social, commercial, and industrial meeting point of the biotechnological...
by Biocross | Sep 21, 2016 | News
The diagnosis of Alzheimer’s disease is established through a series of neuropsychological tests, images obtained by MRI or CT scan, and the analysis of markers obtained by lumbar puncture. “Diagnosis is reached by putting together all this...
by Biocross | Jul 5, 2016 | Press release
Biocross is pleased to present at the 2016 Alzheimer’s Association International Conference (AAIC) in Toronto its work on the influence of APOE ε4 carrier status on the metabolomic profile of AD patients versus cognitively normal controls. The AAIC is the...
by Biocross | Mar 2, 2016 | Press release
Biocross has appointed Matthew Mittino as its new CEO. Biocross is currently developing several projects centered on the diagnosis of Alzheimer’s disease and the identification of populations at risk of developing the disease. Over the last 20 years Matthew’s...
